ES2526537T3 - Método para optimizar con imatinib el tratamiento de enfermedades proliferativas mediadas por el receptor kit de tirosina quinasa - Google Patents
Método para optimizar con imatinib el tratamiento de enfermedades proliferativas mediadas por el receptor kit de tirosina quinasa Download PDFInfo
- Publication number
- ES2526537T3 ES2526537T3 ES09704256.8T ES09704256T ES2526537T3 ES 2526537 T3 ES2526537 T3 ES 2526537T3 ES 09704256 T ES09704256 T ES 09704256T ES 2526537 T3 ES2526537 T3 ES 2526537T3
- Authority
- ES
- Spain
- Prior art keywords
- imatinib
- pharmaceutically acceptable
- acceptable salt
- treatment
- cmin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000005517 L01XE01 - Imatinib Substances 0.000 title claims abstract description 72
- 229960002411 imatinib Drugs 0.000 title claims abstract description 72
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 201000010099 disease Diseases 0.000 title description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 19
- 238000000034 method Methods 0.000 title description 18
- 230000001404 mediated effect Effects 0.000 title description 13
- 230000002062 proliferating effect Effects 0.000 title description 13
- 102000005962 receptors Human genes 0.000 title description 3
- 108020003175 receptors Proteins 0.000 title description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 230000035772 mutation Effects 0.000 claims description 13
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical class CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 12
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 8
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 8
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 6
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 5
- 201000008736 Systemic mastocytosis Diseases 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000007033 Dysgerminoma Diseases 0.000 description 2
- 208000035268 Mast Cell Activation disease Diseases 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 201000010208 Seminoma Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- -1 4-methyl-piperazino-methyl Chemical group 0.000 description 1
- 201000008217 Aggressive systemic mastocytosis Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2294508P | 2008-01-23 | 2008-01-23 | |
| US22945P | 2008-01-23 | ||
| PCT/US2009/031510 WO2009094360A1 (en) | 2008-01-23 | 2009-01-21 | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2526537T3 true ES2526537T3 (es) | 2015-01-13 |
Family
ID=40435094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09704256.8T Active ES2526537T3 (es) | 2008-01-23 | 2009-01-21 | Método para optimizar con imatinib el tratamiento de enfermedades proliferativas mediadas por el receptor kit de tirosina quinasa |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20100298338A1 (enExample) |
| EP (1) | EP2237783B1 (enExample) |
| JP (2) | JP5936821B2 (enExample) |
| KR (1) | KR101579993B1 (enExample) |
| CN (1) | CN101951910B (enExample) |
| AU (1) | AU2009206566A1 (enExample) |
| BR (1) | BRPI0906504A2 (enExample) |
| CA (1) | CA2712087A1 (enExample) |
| ES (1) | ES2526537T3 (enExample) |
| MX (1) | MX2010008103A (enExample) |
| PL (1) | PL2237783T3 (enExample) |
| PT (1) | PT2237783E (enExample) |
| RU (1) | RU2537223C2 (enExample) |
| WO (1) | WO2009094360A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753391C1 (ru) * | 2020-09-29 | 2021-08-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0127922D0 (en) * | 2001-11-21 | 2002-01-16 | Novartis Ag | Organic compounds |
| SI1686997T1 (sl) * | 2003-11-18 | 2009-08-31 | Novartis Ag | Inhibitorji mutantne oblike KIT |
| US7329495B2 (en) * | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| EP2251042A3 (en) * | 2006-09-22 | 2012-05-02 | Novartis AG | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
| CA2668828A1 (en) | 2006-11-07 | 2008-05-29 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
-
2009
- 2009-01-21 EP EP09704256.8A patent/EP2237783B1/en not_active Revoked
- 2009-01-21 US US12/863,627 patent/US20100298338A1/en not_active Abandoned
- 2009-01-21 MX MX2010008103A patent/MX2010008103A/es active IP Right Grant
- 2009-01-21 BR BRPI0906504-0A patent/BRPI0906504A2/pt not_active IP Right Cessation
- 2009-01-21 PL PL09704256T patent/PL2237783T3/pl unknown
- 2009-01-21 CN CN2009801027282A patent/CN101951910B/zh not_active Expired - Fee Related
- 2009-01-21 JP JP2010544393A patent/JP5936821B2/ja not_active Expired - Fee Related
- 2009-01-21 CA CA2712087A patent/CA2712087A1/en not_active Abandoned
- 2009-01-21 KR KR1020107018386A patent/KR101579993B1/ko not_active Expired - Fee Related
- 2009-01-21 RU RU2010134916/15A patent/RU2537223C2/ru not_active IP Right Cessation
- 2009-01-21 AU AU2009206566A patent/AU2009206566A1/en not_active Abandoned
- 2009-01-21 PT PT97042568T patent/PT2237783E/pt unknown
- 2009-01-21 ES ES09704256.8T patent/ES2526537T3/es active Active
- 2009-01-21 WO PCT/US2009/031510 patent/WO2009094360A1/en not_active Ceased
-
2013
- 2013-12-18 JP JP2013261728A patent/JP5881671B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-27 US US14/924,207 patent/US20160045501A1/en not_active Abandoned
-
2016
- 2016-10-19 US US15/297,372 patent/US9763944B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2237783B1 (en) | 2014-11-19 |
| PT2237783E (pt) | 2014-12-23 |
| PL2237783T3 (pl) | 2015-04-30 |
| AU2009206566A1 (en) | 2009-07-30 |
| CA2712087A1 (en) | 2009-07-30 |
| US20170035757A1 (en) | 2017-02-09 |
| CN101951910A (zh) | 2011-01-19 |
| WO2009094360A1 (en) | 2009-07-30 |
| JP2011510086A (ja) | 2011-03-31 |
| JP2014094946A (ja) | 2014-05-22 |
| RU2537223C2 (ru) | 2014-12-27 |
| US9763944B2 (en) | 2017-09-19 |
| RU2010134916A (ru) | 2012-02-27 |
| EP2237783A1 (en) | 2010-10-13 |
| JP5881671B2 (ja) | 2016-03-09 |
| US20100298338A1 (en) | 2010-11-25 |
| KR20100105778A (ko) | 2010-09-29 |
| JP5936821B2 (ja) | 2016-06-22 |
| CN101951910B (zh) | 2013-07-17 |
| KR101579993B1 (ko) | 2015-12-23 |
| MX2010008103A (es) | 2010-08-23 |
| US20160045501A1 (en) | 2016-02-18 |
| BRPI0906504A2 (pt) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088616A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| JP5948246B2 (ja) | Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法 | |
| ES2953005T3 (es) | Tratamiento para el cáncer | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| US20100210673A1 (en) | Pyrimidylaminobenzamide derivatives for systemic mastocytosis | |
| TW202423445A (zh) | 英菲格拉替尼在治療胃癌和腺癌中的用途 | |
| ES2526537T3 (es) | Método para optimizar con imatinib el tratamiento de enfermedades proliferativas mediadas por el receptor kit de tirosina quinasa | |
| AU2013201993B2 (en) | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib | |
| RU2695362C2 (ru) | Новое сочетание з-[(3-{ [4-(4-морфолинилметил)-1н-пиррол-2-ил]метилен} -2-оксо-2,3-дигидро-1н-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr | |
| CN1671389A (zh) | 用于治疗间变性甲状腺癌的4－(4－甲基哌嗪－1－基甲基)－n－[4－甲基－3－基)嘧啶－2－基氨基)苯基]－苯甲酰胺 |